Peter A. Merkel

Jul 30, 2024 | healio.com | Rob Volansky |Shenaz Bagha |Peter A. Merkel

Read more You've successfully added Vasculitis and Giant Cell Arteritis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Feb 16, 2024 | cgtlive.com | Peter A. Merkel

This is the third part of an interview with Peter A. Merkel, MD, MPH. For the first part, click here. “I think there’s an excitement, but a cautious optimism about this area. I think we are certainly hopeful that some forms of cell-based therapy will help some forms of autoimmune disease and hopefully substantially. We need to do this right, we need to move it forward, but I think we're very enthused.

Feb 10, 2024 | cgtlive.com | Peter A. Merkel

February 10, 2024The chief of the Division of Rheumatology and professor of medicine and professor of epidemiology at Penn Medicine discussed the panel he participated in at the inaugural Cell Therapy for Autoimmune Disease Summit. “This probably needs to work moderately to extremely well for it to be worth it economically and in a risk-benefit standpoint. But I think there are real opportunities here to take our treatments to another level to help our patients. But caution is appropriate.

Sep 9, 2023 | healio.com | Rob Volansky |Shenaz Bagha |Peter A. Merkel

Source/Disclosures Source: Merkel P. Large-Vessel Vasculitis in 2023. Presented at The Congress of Clinical Rheumatology West; Sept. 7-10, 2023 (hybrid meeting).

Aug 29, 2023 | acrjournals.onlinelibrary.wiley.com | Zachary S. Wallace |John Stone |Xiaoqing Fu |Peter A. Merkel

Objective Fixed and tailored rituximab retreatment strategies to maintain remission in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) are associated with tradeoffs. The current study was undertaken to develop a simulation model (AAV-Sim) to project clinical outcomes with these strategies. Methods We developed the AAV-Sim, a microsimulation model of clinical events among individuals with AAV initiating treatment to maintain remission.